| Literature DB >> 23369718 |
Xiaobing He1, Huaijie Jia, Zhizhong Jing, Dingxiang Liu.
Abstract
Foreign nucleic acids, the essential signature molecules of invading pathogens that act as danger signals for host cells, are detected by endosomal nucleic acid-sensing toll-like receptors (TLRs) 3, 7, 8, 9, and 13. These TLRs have evolved to recognize 'non-self' nucleic acids within endosomal compartments and rapidly initiate innate immune responses to ensure host protection through induction of type I interferons, inflammatory cytokines, chemokines, and co-stimulatory molecules and maturation of immune cells. In this review, we highlight our understanding of the recognition of pathogen-associated nucleic acids and activation of corresponding signaling pathways through endosomal nucleic acid-sensing TLRs 3, 7, 8, 9, and 13 for an enormous diversity of pathogens, with particular emphasis on their compartmentalization, intracellular trafficking, proteolytic cleavage, autophagy, and regulatory programs.Mesh:
Substances:
Year: 2013 PMID: 23369718 PMCID: PMC7109797 DOI: 10.1093/abbs/gms122
Source DB: PubMed Journal: Acta Biochim Biophys Sin (Shanghai) ISSN: 1672-9145 Impact factor: 3.848
Summary of the signaling pathways of TLR3, 7, 8, 9, and 13
| Type | Subcellular localization | Natural and synthetic ligand | Adaptor | Transcription factor | Effector cytokines | References |
|---|---|---|---|---|---|---|
| TLR3 | Endosomes | dsRNAs, siRNAs, poly(I:C) | TRIF | NF-κB, AP-1, IRF3 | Inflammatory cytokines, type I interferons | [ |
| TLR7 | Endosomes | ssRNAs, ORNs, siRNAs, imidazoquinolines | MyD88, PACSIN1 | NF-κB, AP-1, IRF3/7 | Inflammatory cytokines, type I interferons | [ |
| TLR8 | Endosomes | ssRNAs, ORNs, siRNAs, poly(A)/T, DNA, imidazoquinolines | MyD88 | NF-κB, AP-1, IRF3/7 | Inflammatory cytokines, type I interferons | [ |
| TLR9 | Endosomes | CpG DNAs, CpG ODNs | MyD88, PACSIN1 | NF-κB, AP-1, IRF3/7 | Inflammatory cytokines, type I interferons | [ |
| TLR13 | Endosomes | 23S rRNA | MyD88 | NF-κB, AP-1, IRF3/7 | Inflammatory cytokines, type I interferons | [ |
List of pathogens recognized by TLR3, 7, 8, 9, and 13
| Receptors | Pathogens | References |
|---|---|---|
| TLR3 |
| |
| Reovirus | [ | |
| Respiratory syncytial virus | [ | |
| West Nile virus | [ | |
| Dengue virus | [ | |
| Influenza A virus | [ | |
| Encephalomyocarditis virus | [ | |
| Lymphocytic choriomeningitis virus | [ | |
| Semliki forest virus | [ | |
| Coxsackievirus group B serotype 3 | [ | |
| Poliovirus | [ | |
| Punta Toro virus | [ | |
| Epstein-Barr virus | [ | |
| Hepatitis C virus | [ | |
| Kaposi's sarcoma-associated herpesvirus | [ | |
| Vaccinia virus | [ | |
| Herpes simplex virus | [ | |
| Mouse cytomegalovirus | [ | |
|
| ||
| | [ | |
|
| ||
| | [ | |
| TLR7 and/or TLR8 |
| |
| Vaccinia virus | [ | |
| Modified VV Ankara | [ | |
| Human immunodeficiency virus | [ | |
| Influenza A virus | [ | |
| Sendai virus | [ | |
| Vesicular stomatitis virus | [ | |
| Coxsacki B virus | [ | |
| Human parechovirus 1 | [ | |
| Foot and mouth disease virus | [ | |
| Newcastle disease virus | [ | |
| Dengue virus | [ | |
| Hepatitis C virus | [ | |
| Mouse hepatitis virus | [ | |
| Pneumonia virus of mice | [ | |
| Mouse mammary tumor virus | [ | |
| Murine leukemia virus | [ | |
|
| ||
| | [ | |
| | [ | |
| | [ | |
| | [ | |
| Group B | [ | |
|
| ||
| | [ | |
|
| ||
| | [ | |
| | [ | |
| TLR9 |
| |
| Human papillomavirus | [ | |
| Herpes simplex virus 1/2 | [ | |
| Mouse cytomegalovirus | [ | |
| Adenovirus | [ | |
| Baculovirus | [ | |
| Epstein-Barr virus | [ | |
| Human herpesvirus type 6B | [ | |
| Varicella-zoster virus | [ | |
| Murine gammaherpesvirus 68 | [ | |
| Ectromelia virus | [ | |
|
| ||
|
| [ | |
|
| [ | |
|
| [ | |
|
| [ | |
| M1T1 group A | [ | |
|
| [ | |
|
| ||
|
| [ | |
|
| [ | |
|
| [ | |
|
| [ | |
|
| ||
|
| [ | |
|
| [ | |
|
| [ | |
|
| [ | |
|
| [ | |
| TLR13 |
| |
| Vesicular stomatitis virus | [ | |
|
| ||
|
| [ | |
|
| [ |
List of regulatory molecules required for TLR3, 7, 8, 9, and 13 signaling pathways
| Regulators | Targets | Regulatory mechanisms | Effectors | References | |
|---|---|---|---|---|---|
| Positive regulation | TRAF6 | TRAF6, cIAP1/2, IRAKs | Ubiquitination of targets | Activation of TAK1, TBK1 and IKKi | [ |
| Ubc5 | IRF3 | Ubiquitination of IRF3 | Activation of IRF3 | [ | |
| MARCH5 | TANK | Polyubiquitination of TANK | Activation of IRF7 | [ | |
| Viperin | IRAK1, TRAF6 | Polyubiquitination of IRAK1 | Activation of IRF7 | [ | |
| SUMO | TANK | SUMOylation of TANK | Controls IKKɛ-TBK1 interactions | [ | |
| Nrdp1 | TBK1 | Ubiquitination of TBK1 | Activation of TBK1 and IRF3 | [ | |
| miR-181b-1 | CYLD | Inhibits CYLD production | Activation of NF-kB | [ | |
| Negative regulation | Triad3A | TLR9 | Ubiquitination and proteolytic degradation of TLR9 | Inhibition TLR9 activation | [ |
| ST2L | MyD88 | Sequestration of MyD88 | Inhibition TLR9 activation | [ | |
| SIGIRR | TRAF6, IRAK | Inhibition of TRAF6 and IRAK | Inhibition TLR9 activation | [ | |
| PI3 | p38, JNK, NF-κB | Inhibition NF-κB and AP-1 activation | Inhibition of cytokine production | [ | |
| TRIM30α | TAB2, TAB3 | Lysosome-related degradation of TAB2 and TAB3 | Inhibition NF-κB activation | [ | |
| Nrdp1 | MyD88 | Proteosomal degradation of MyD88 | Inhibition IRAK1, TAK1, IKKβ, MAPKs, and NF-κB activation | [ | |
| A20 | RIP1, TRAFs, TRIF, cIAP1/2, and IKK complex | Ubiquitination or deubiquitination of targets, and disruption of protein–protein interaction | Inhibition NF-κB and IRF3 activation | [ | |
| DUBA | TBK1 | Ubiquitination of TBK1 | Inhibition of TRAF3 and IRFs | [ | |
| CYLD | TBK1 | Ubiquitination of TBK1 | Inhibition of TRAF3 and IRFs | [ | |
| OTUB1, OTUB2 | TRAF3/6 | Ubiquitination of TRAF3/6 | Inhibition of NF-κB and IRF3 activation | [ | |
| TANK | TRAF6 | Ubiquitination of TRAF6 | Inhibition of NF-κB and AP-1 activation | [ | |
| Atg16L1 | TRIF | Surpression of TRIF-dependent pathway | Suppression of caspase-1 activation | [ | |
| SHP-2 | TBK1 | Phosphorylation of TBK1 | Inhibition of cytokine production | [ | |
| SHP-1 | IRAK1, IRAK2 | IRAK1 and IRAK2 | Inhibition of cytokine production | [ | |
| CD2AP | Cbl | Ubiquitination of Cbl | Inhibition of TLR9-mediated type 1 IFN production | [ | |
| sTLR9 | TLR9 | Sequestration of TLR9 | Inhibition of TLR9-mediated signaling activation | [ | |
| IRAKM | IkBa, IRAK-1 | Phosphorylation of IkBa, Inhibition of IRAK-1 | Inhibition of cytokine production | [ | |
| MyD88s | MyD88 | Sequestration of MyD88 | Inhibition of MyD88-mediated signaling activation | [ | |
| SARM | TRIF | Sequestration of TRIF | Inhibition of TRIF-mediated signaling activation | [ | |
| IRF4 | IRF5 | Sequestration of IRF5 | Inhibition of TLR signaling activation | [ | |
| miR-146 | TRAF6, IRAK1/2 | down-regulates IRAK1/2 and TRAF6 | Inhibition of the MyD88/NF-kB signaling activation | [ | |
| miR-155 | IKKi, IKKβ, TAB2, and MyD88 | Inhibition of IKKi and IKKβ | Inhibition of NF-κB activation | [ | |
| miR-9 | p105, p50 | Inhibition of p50/p52 mature | Modulation of the NF-kB pathway | [ | |
| miR-199a, miR-214 | IKKβ | down-regulates IKKβ | Inhibition of NF-kB activity | [ | |
| miR-223, miR-15, miR-16 | IKKα, NIK, TRAF2, and p52 | Inhibition of targets | Inhibition of noncanonical NF-kB pathway | [ | |
DUBA, deubiquitinating enzyme A; CYLD, cyclindomatosis.